Natural killer (NK) cytotoxic activity was simultaneously investigated in bone marrow mononuclear cells (BMMC) and peripheral blood lymphocytes (PBL) from nine Hodgkin's disease (HD) and 15 non-Hodgkin lymphoma (NHL) untreated patients. Twenty-five PBL samples and seven bone marrow specimens from healthy individuals were also included as control group (C). NK cell activity was evaluated in basal condition and post-stimulation with human recombinant IL-2 (rIL-2). Data were expressed in Kvalues (number of BMMC or PBL needed to lyse 50% of the target cells). In basal condition, both HD and NHL patients showed a NK cell activity comparable to the C group, both in BMMC (HD, K=248+13; NHL, K= 38+220; C, K= 3 2+0 7) and PBL (HD, K= 2-0+I-0; NHL, K= 2-3 + I 0; C, K= 2 2 + 0 2). Stimulation with rIL-2 induced a significant and comparable enhancement of the NK activity in PBL from HD, NHL and C while the response to rIL-2 of the BMMC in most of the HD and NHL patients was significantly greater than the C group. Responder cells were characterized by negative selection with specific MoAb plus complement as a CD3-, CD16+, CD56+ cytotoxic cell and further confirmed by flow cytometry. We postulate that IL-2 activation of bone marrow NK cell precursors, in addition to enhancing the activity of circulating NK, may be df value for the therapeutic rationale of IL-2 in patients with lymphoma.
INTRODUCTION
Natural killer (NK) cells have been proposed as the first line of defence against tumour and virus-infected cells [1] . These cells arise from bone marrow (BM) precursors, independently of thymic influence [2] [3] [4] and their maturation and spontaneous cytotoxic activity is dependent on continued exposure to IL-2 [4] [5] [6] . It has been shown that most of the NK function is exerted by a lymphocyte subset known as large granular lymphocytes (LGL) [7] , which in addition to their cytotoxic activity is able to secrete a variety of cytokines [8] [9] [10] . Although in vitro evidence suggests that NK activity may have an important regulatory role against malignant lymphoproliferative diseases [11] , NK function has been poorly evaluated in patients with these malignancies. Furthermore, the few available reports in the literature have focused on NK activity only in the peripheral blood (PB) compartment [12, 13] . To our knowledge, no previous report has simultaneously evaluated NK function in both BM and PB compartments of patients with Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) .
In the present investigation, untreated patients with HD and NHL were evaluated for NK activity in BM and PB against Correspondence: Isaac Blanca MSc, Apartado Postal 50109, Caracas 1050-A, Venezuela. 143 K562 cell line, both in basal condition and post-stimulation with human recombinant IL-2 (rIL-2).
MATERIALS AND METHODS

Patients
Twenty-four untreated lymphoma patients (nine HD and 15 NHL) aged 9-65 years were studied. The clinical protocol included clinical and histological parameters. Within the latter, the Rye Conference Nomenclature [14] for HD and the Working Formulation of Non-Hodgkin Lymphomas for Clinical Usage [15] for NHL was used. Staging of the disease was established following the guidelines of the Ann Arbor Conference [16] .
Histological subtypes in the nine patients with HD were nodular sclerosis (three) and mixed cellularity (six); NHL patients were classified as low (five), intermediate (seven) and high grades of malignancy (three), according to the prognostic group. NK activity of non-adherent PBMC and BMMC was evaluated by a 5'Cr-release assay as previously described [21] . Briefly, 5 x 103 5"Cr-labelled target cells in 0 1 ml were mixed with 0.1 ml ofeffector cells (PBMC or BMMC) at three different effector/target cell ratios (40: 1, 20: 1 and 10: 1). Each combination was seeded in triplicate in U-bottomed microtest plates (Falcon Plastics, USA). Triplicates of target cells K562 plus medium were included to measure the spontaneous release. Plates were incubated for 4 h at 37°C in a humidified atmosphere of 5% C02-air mixture. Finally, the cells were pelleted by centrifugation at 400 g for 10 min and 0 1 ml of the supernatant (per well) was harvested and 51Cr release was measured in a gamma counter (LKB Compugamma, Wallac, Sweden). Total release was determined by counting 5 x 103 lysed K562 labelled cells. The percent of specific lysis was calculated by the following formula:
Controls
'/o specific lysis= mean experimental release (ct/min) -mean spontaneous release (ct/min) x 100 mean total release (ct/min) -mean spontaneous release (ct/min)
The data were also expressed as the number of mononuclear cells required for 50% specific 5'Cr release from 5 x 103 K562 target cells (K), calculated by the Trinchieri-modified Von Krogh equation [22] as previously described [23] . Peripheral blood NK activity As shown in Table 3 , non-significant differences were observed in the basal PBMC NK activity among the three groups (HD, K=2-0+1-Ox105 cells; NHL, K=2-3+ 1-0x105 cells; C, The rIL-2 stimulation induced a significant enhancement of PBMC NK activity in the majority of the patients and in all the controls (Fig. 1) . Only three out ofeight in HD and two out of 11 NHL were not responders to rIL-2. No correlation was found between the stage or degree of the lymphoma and the response to rIL-2.
Bone marrow NK activity Table 4 shows the K values and its corresponding RK obtained from six HD, 12 NHL patients and seven control individuals, all tested for NK activity under basal condition and after adding rIL-2. As determined by K values and the RK, the basal NK activity in the five HD patients was comparable to or higher than the mean control activity. In NHL, 50% of these patients also showed a NK activity higher than the mean control value. The RK of rIL-2-stimulated BMMC indicated that 60% of HD Effect ofthe depletion ofCD3 or CD56 lymphocyte subsets on the cytotoxic activity In order to characterize the rIL-2 activated effector cells in both PBMC and BMMC, samples from five patients (one HD and four NHL) and five controls were subjected to NK or T cell depletion before stimulation with IL-2. As shown in Table 5 , depletion of CD3+ cells before rIL-2 stimulation did not affect the cytolytic activity of PBMC or BMMC. In contrast, depletion of NK cells with NKH-1A (anti-CD56) plus complement totally abolished the cytotoxic activity in both PBMC and BMMC. Although the IL-2 stimulated killer cells were also tested against a long-term cultured B leukaemia cells, resistant to NK cells, LAK activity was not observed during the selected time (18 h) of incubation rIL-2 (data not shown). A longer period of incubation was not possible to evaluate due to the small number of cells recovered after the depletion procedure.
DISCUSSION
In patients with lymphoid malignancies, cell-mediated immunity, particularly related to T cells [25] [26] [27] , and to macrophagemediated functions [28] commonly exhibits significant alterations. However, very few studies are available dealing with the peripheral blood NK activity in HD and NHL patients. Furthermore, the available results are conflicting. Thus, while some laboratories reported significantly depressed NK activity in HD and NHL patients [12, 13, 27] , Gupta & Fernandez [29] have reported a normal NK function in HD patients. To our knowledge, no previous studies have simultaneously examined the NK activity in both PB and BM compartments of patients with HD and NHL.
We basically report on findings related to the nature of NK cell activity in PB and BM from untreated HD and NHL patients. Furthermore, we employed the K value and RK as useful methods to compare NK lytic activity between patients and controls. The application of the RK method to patient populations has the advantage of relating to actual lytic activity as well as reducing intra-assay variation in data expression [24] . It also makes the comparison of results between patients and controls simpler, since the average value for a normal NK activity is by definition 1 0. The application of this criterion to our data permitted us to easily compare patients and controls on an individual basis.
Contrary to previous reports [13, 27] , our results indicate that PBMC NK cell number and lytic activity are comparable to the controls in both HD and NHL patients. These findings are consistent with those by Gupta & Fernandez [29] . Furthermore, in our patients and controls, rIL-2 induced a significant enhancement of NK activity in both PBMC and BMMC. Moreover, a remarkably higher increase in the BM compartment was noted in many of the HD and NHL patients when compared to the C group. This higher response of the patients' BMMC may be due to an elevated number of NK cell precursors being induced to maturation with rIL-2, since the number of mature NK cells in the BM from patients and controls was not significantly different. This hypothesis is supported by studies showing that the generation of high or low NK cell activity is predetermined at BM precursor level [2] ; studies on NK regulation have shown that mouse [30] and human NK cells [31] proliferated in response to IL-2 and that NK cell activity is dependent on their continuous exposure to IL-2 [6] . Furthermore, studies in mouse BM cells [2, 32, 33] [34] . However, recent studies by Jhaver [34] have shown that lymphokine-activated killer (LAK) cells generated from peripheral blood of NHL patients expressed a comparable level of cytotoxicity to the control group. Furthermore, the patients with advanced disseminated disease displayed a better augmentation under rIL-2 than the patients with localized disease.
In our study, some patients with advanced HD (Table 1 No. 3, 6 and 8) and NHL (No. 1, 6 and 11) also showed a higher response to rIL-2 in the PBMC, using a short-term 18 h incubation, suggesting that the potential response to rIL-2 is maintained or even increased in both types of malignancies.
Very few reports on the application of IL-2 therapy to lymphoma are available [35] . However, both preclinical and clinical data suggest that lymphoid malignancies may be highly susceptible to IL-2 therapy [36] [37] [38] .
Our results offer additional support to the possibility that IL-2 activation of NK cells from BM precursors, in addition to enhancing the NK circulating cell activity, may be of value for the therapeutic rationale of IL-2 in patients with lymphomas.
